New hope for hard-to-treat lymphoma: experimental combo enters final testing phase

This study tests whether adding the experimental drug IMM0306 to the standard drug lenalidomide helps people with relapsed or refractory follicular lymphoma. About 198 adults whose cancer has not responded to at least two prior treatments will be randomly assigned to receive either IMM0306 or a placebo, both combined with lenalidomide. The main goals are to see if the combination leads to complete cancer disappearance and longer time without the disease worsening.